Abstract 1738: Assay development for detecting cMET expression in circulating tumor cells (CTC), a potential patient tailoring marker for evaluation of cMET inhibitors
S. Betty Yan(Cardiovascular Institute Hospital), Richard A. Walgren(Eli Lilly (United States)), Ling L. Liu(Eli Lilly (United States)), Victoria L. Peek(Eli Lilly (United States)), Lei Yan(Shandong Tumor Hospital), Wei Zeng, Sunil Kadam(Eli Lilly (United States)), John T. Brandt(Universitätsklinikum Würzburg), Suzane L. Um(Eli Lilly (United States)), Lee A. O’Brien(University of Wisconsin–Madison)
Cited by 1
Related Papers
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
|American Heart Journal|2006|571
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
|European Heart Journal|2006|537
The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study
|Blood|2006|351
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently
|Clinical Pharmacology & Therapeutics|2007|323
A Comparison of Methods for Modeling Quantitative Structure−Activity Relationships
|Journal of Medicinal Chemistry|2004|233